Analyze Catalogue Methodology Blog Pro Access

⚡ Interrogation des APIs scientifiques en cours…

The quality score for scientific publications. 100% free, 100% independent.

Navigation

Home
Analyze an article
Methodology
Blog
My account

Transparency

Our independence
Methodological transparency
Pro Access
Contact us
Legal notice
Privacy
ToU
ToS
Glossary

Developers

Public API
GitHub

Free score, forever.

B (61/100) — Plutôt fiable | Schulze MB et al. | Publi-Score

Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women

Schulze MB et al.·JAMA·Aug 2004·PMID 15328324

Authors' conclusion

Positive

Does not affect the score

Publi-Score

61/100

Mostly reliableLast updated: 4/18/2026

Fidelity

Abstract only65% concordance × 24/26 subcriteria

Category breakdown

Total raw score38.8/100

Integrity coefficient

A. Authors' integrity

COI declaration

0.65

Funding independence

1.00

Coeff. authors = avg(0.65, 1.00) = 0.83

B. Editorial process

Peer review

1.00

Submission→accept. delay

0.90

Coeff. editorial = avg(1.00, 0.90) = 0.95

min(0.83, 0.95) = 0.83← lowest dominates

Final coefficient : 0.83

Final score = 38.8/52.8 × 0.83 × 100 = 61/100

Save

📄 Export PDF

PubMed DOI

Twitter/X LinkedIn

Contribute

Actions

Analyze another article View the methodology

Information

PMID: 15328324
DOI

10.1001/jama.292.8.927

Mode

🔬 Partial AI (abstract)

Grid

v1.1

Scored on

4/18/2026

Impact Factor

120.7

Quartile

Similar publications

Contrasted results

D41/100

A randomized trial of sugar-sweetened beverages and adolescent body weight.

Ebbeling CB — 2012 · New England Journal of Medicine

Contrasted results

D37/100

Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomi…

Hall KD — 2019 · Cell Metabolism

C52/100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray JJV — 2019 · The New England journal of medicine

B70/100

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised stat…

Sattar N — 2010 · Lancet

D43/100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Zinman B — 2015 · New England Journal of Medicine